Recurrent Pericarditis After Atrial Fibrillation Ablation
Pericardial inflammation is a recognized complication of catheter ablation for atrial fibrillation (AF). Most patients experience a short-lived inflammatory response that resolves with supportive treatment, yet a small proportion develop persistent or recurrent symptoms. The presentation may resemble ordinary post-procedural chest discomfort, making careful assessment essential.
The clinical challenge is to distinguish recurrent pericarditis from expected post-ablation pain, recurrent atrial arrhythmia, coronary ischemia, pulmonary embolism, delayed tamponade, or an atrioesophageal fistula. Diagnosis therefore depends on symptom timing, physical findings, electrocardiography, imaging, inflammatory markers, and a review of the ablation procedure.
Management combines anti-inflammatory therapy with decisions about anticoagulation, rhythm monitoring, and repeat imaging. Because the evidence base is smaller than that for idiopathic or post-pericardiotomy pericarditis, clinicians must adapt established principles to the post-AF ablation setting.
Why Inflammation Develops After Ablation
Radiofrequency and pulsed-field ablation create controlled myocardial injury to isolate pulmonary veins or modify other atrial substrates. Tissue necrosis can stimulate the innate immune system, producing cytokine release, pleuritic pain, fever, and pericardial irritation. Cryoballoon ablation can produce a similar inflammatory response, although the pattern and extent of tissue injury differ.
Symptoms commonly appear within days of the procedure, but delayed presentations can occur several weeks later. Patients may report sharp, positional chest pain that improves when sitting forward, dyspnea, low-grade fever, or fatigue. A pericardial friction rub, diffuse ST-segment elevation, or PR-segment depression supports the diagnosis, although none is present in every case.
Prior thoracic surgery, extensive atrial ablation, and repeat procedures may affect the inflammatory risk and the differential diagnosis. Special procedural considerations in patients with previous operations are discussed in this clinical review of prior cardiac surgery, particularly when altered anatomy or adhesions may complicate interpretation of post-procedure symptoms.
Incidence And Clinical Patterns
The reported incidence of acute pericarditis after AF ablation varies according to the definition used, follow-up period, ablation technology, and whether cases are identified prospectively. Clinically recognized cases are often reported in the range of approximately 0.5% to 2%, while broader definitions that include post-ablation chest pain and inflammatory findings may produce higher estimates.
Recurrence is less consistently measured. Some patients have a single inflammatory episode that resolves after several days of treatment, whereas others experience renewed pain when medication is withdrawn. In general pericarditis populations, recurrence is well recognized, especially after incomplete treatment or premature corticosteroid exposure. After AF ablation, the precise recurrence rate remains uncertain, and available data are frequently derived from retrospective cohorts.
The timing of symptoms can provide useful context. Early pain with a small effusion may reflect acute post-cardiac injury inflammation. Recurrent pain weeks later may indicate ongoing immune activation, inadequate treatment duration, or a new trigger. Atrial tachyarrhythmia itself can also cause chest pressure and breathlessness, so symptom assessment should be paired with rhythm documentation rather than relying on history alone.
Diagnostic Assessment And Red Flags
A practical evaluation begins with a focused history, examination, 12-lead ECG, complete blood count, renal function, C-reactive protein, and troponin when ischemia or myocardial involvement is possible. Transthoracic echocardiography can identify an effusion, assess hemodynamics, and establish a baseline for follow-up. Cardiac magnetic resonance may demonstrate pericardial edema or late gadolinium enhancement when the diagnosis remains uncertain.
Pericarditis is usually supported by at least two compatible findings, such as characteristic chest pain, a friction rub, new widespread ECG changes, or a new or worsening pericardial effusion. Elevated inflammatory markers support active disease and can help guide treatment duration, but normal values do not completely exclude a localized or partially treated process.
Urgent assessment is required for hypotension, rising jugular venous pressure, pulsus paradoxus, syncope, increasing effusion, or signs of tamponade. Fever with systemic toxicity, neurological symptoms, severe dysphagia, gastrointestinal bleeding, or sepsis warrants consideration of an atrioesophageal fistula. Marked troponin elevation, focal ECG changes, or exertional symptoms should prompt evaluation for coronary disease or myocardial injury rather than assuming recurrent pericarditis.
| Clinical situation | Useful evaluation | Management emphasis |
|---|---|---|
| Typical pleuritic pain with stable vital signs | ECG, inflammatory markers, echocardiography | Anti-inflammatory therapy and close review |
| Small or moderate effusion without compromise | Serial echocardiography and symptom assessment | Treat inflammation; monitor for progression |
| Hypotension or suspected tamponade | Immediate echocardiography and specialist review | Urgent drainage and hemodynamic support |
| Recurrent symptoms after treatment withdrawal | CRP, ECG, echocardiography, medication review | Extend therapy and assess adherence or alternative causes |
| Persistent inflammation despite standard treatment | Cardiac imaging and multidisciplinary assessment | Consider corticosteroid-sparing or IL-1-directed therapy |
| Chest pain with major troponin rise or focal changes | Coronary and myocardial evaluation | Manage ischemia or myocarditis as indicated |
First-Line Treatment And Anticoagulation
For patients without contraindications, an NSAID such as ibuprofen or aspirin is commonly used at an anti-inflammatory dose, with gastroprotection when appropriate. Colchicine is frequently added because it can reduce persistent symptoms and recurrence. Dose selection should account for kidney function, liver disease, age, body weight, and interactions with drugs such as certain macrolides or strong CYP3A4 and P-glycoprotein inhibitors.
Treatment should continue until symptoms resolve and inflammatory markers normalize, followed by a gradual reduction in the NSAID or aspirin dose. Colchicine is generally continued for a longer period than the initial analgesic, often several months in recurrent or high-risk disease. Abrupt withdrawal of all therapy while inflammation remains active may increase the likelihood of another flare.
Anticoagulation requires individualized judgment. Most patients undergoing AF ablation have a temporary or ongoing indication for oral anticoagulation based on stroke risk and procedural protocol. Anticoagulation is not automatically stopped because pericarditis is diagnosed, but a large or rapidly expanding effusion raises concern for hemorrhagic complications. Decisions should incorporate the effusion size, hemodynamic status, renal function, bleeding risk, and the patient’s thromboembolic risk, with coordinated input from electrophysiology and cardiology teams.
Managing Recurrent Or Resistant Disease
A recurrence should prompt confirmation that inflammation is still active and that another post-ablation complication has not been overlooked. Medication adherence, insufficient treatment duration, renal dosing, drug interactions, and early corticosteroid use should be reviewed. Repeat echocardiography is appropriate when symptoms change or an effusion was previously documented.
Corticosteroids may be considered when NSAIDs and colchicine are contraindicated, poorly tolerated, or ineffective, or when there is a specific systemic indication. They should generally be prescribed at the lowest effective dose and tapered slowly after clinical and biochemical remission. Rapid tapering can lead to rebound inflammation, while repeated steroid exposure may make future disease more difficult to control.
For steroid-dependent or colchicine-resistant recurrent pericarditis, referral to a specialist with experience in inflammatory cardiac disease is appropriate. Interleukin-1 pathway inhibitors, including anakinra or rilonacept, have demonstrated value in selected recurrent pericarditis populations, although access, infection risk, vaccination status, cost, and regulatory considerations influence their use. Evidence specifically targeting recurrence after AF ablation remains limited, so treatment should be individualized and documented carefully.
Follow-Up, Rhythm Care, And Prevention
Follow-up should assess pain, exercise tolerance, fever, medication adverse effects, renal function, inflammatory markers, and effusion size when clinically indicated. Patients should receive clear instructions to report worsening breathlessness, syncope, persistent fever, or rapidly increasing chest pain. Exercise restriction is reasonable during active inflammation, particularly when myocardial involvement has not been excluded.
Atrial fibrillation may recur during the blanking period because inflammation and autonomic changes can transiently increase atrial irritability. Palpitations should therefore be evaluated with an ECG, ambulatory monitor, or implanted device interrogation rather than automatically attributed to pericarditis. Antiarrhythmic therapy and rate control may be required temporarily, while decisions about repeat ablation should wait until active inflammation and reversible triggers have been addressed.
Preventive strategies remain an area of investigation. Colchicine around the time of ablation has been studied in several settings, but results have varied with dose, duration, ablation method, and outcome definition. Routine prophylaxis cannot be separated from bleeding risk, gastrointestinal tolerance, kidney function, and local practice. The most reliable preventive measures are careful procedural planning, early recognition, adequate treatment of the first episode, and structured follow-up.
Practical Priorities For Clinical Teams
- Document the onset, character, and position-related nature of chest pain after ablation.
- Use ECG, inflammatory markers, and echocardiography to support diagnosis and establish severity.
- Exclude tamponade, myocardial ischemia, pulmonary embolism, and atrioesophageal fistula when warning signs are present.
- Combine an appropriate anti-inflammatory agent with colchicine when suitable, and taper treatment after objective remission.
- Coordinate anticoagulation decisions with electrophysiology and cardiology specialists rather than making an automatic interruption.
- Refer recurrent, steroid-dependent, or treatment-resistant cases for specialist inflammatory disease management.
Recurrent symptoms after AF ablation deserve a structured assessment rather than reassurance alone. Better characterization of incidence, procedural risk factors, biomarkers, and preventive therapy will help clinicians distinguish transient inflammation from a disease course requiring prolonged treatment. Readers can follow emerging evidence through the Journal of Arrhythmia’s research and educational resources, and investigators developing relevant studies can contact the journal team to engage with its clinical and scientific community.